Professor Isabelle C. Van Gelder co-chaired the guideline task force on the 2024 ESC Guidelines for the Management of Atrial Fibrillation.

Video: https://medicaldigest.org/scientific-contents/interview:2024-esc-guidelines-management-atrial-fibrillation-report-esc2024

Professor Christiaan Vrints co-chaired the guideline task force on the 2024 ESC Guidelines for the Management of Chronic Coronary Syndromes.

Video: https://medicaldigest.org/scientific-contents/interview:2024-esc-guidelines-management-chronic-coronary-syndromes-report-esc2024

Professor Gi-Byoung Nam explains thtat edoxaban monotherapy reduced net adverse clinical events compared with edoxaban plus a single antiplatelet agent, when used as long-term antithrombotic therapy, in patients with high-risk atrial fibrillation and stable coronary artery disease, according to late-breaking research presented in a Hot Line session at ESC Congress 2024.

Video: https://medicaldigest.org/scientific-contents/interview:epic-cad-edoxaban-monotherapy-vs-dual-antithrombotic-therapy-atrial-fibrillation-and-stable-coronary-artery-disease-report-esc2024

Professor Muthiah Vaduganathan explains that the FINE-HEART pooled analysis of three large trials failed to demonstrate significant reductions in cardiovascular death with finerenone, but significantly lower all-cause mortality, cardiovascular events and kidney outcomes were observed, according to late-breaking research presented in a Hot Line session at ESC Congress 2024.

Video: https://medicaldigest.org/scientific-contents/interview:fine-heart-participant-level-pooled-analysis-finerenone-heart-failure-and-chronic-kidney-disease-trials

Professor Mario Marzilli highlights the evolving environment of chronic coronary syndrome management and translates new ESC chronic coronary syndrome guidelines into clinical practice.

Video: https://medicaldigest.org/scientific-contents/interview:chronic-ischaemic-syndrome-management-2024-are-we-ready-revolution-report-esc2024

Professor Pardeep Jhund explains that mineralocorticoid receptor antagonists reduced the risk of cardiovascular death or heart failure hospitalization in patients with HF and reduced ejection fraction and also in those with mildly reduced or preserved ejection fraction, according to late-breaking research presented in a Hot Line session at ESC Congress 2024.

Video: https://medicaldigest.org/scientific-contents/interview:mineralocorticoid-receptor-antagonists-heart-failure-individual-patient-level-meta-analysis

Professor Ramzi Ajjan shares his insights on cardio-renal protection in patients with diabetes.

Video: https://medicaldigest.org/scientific-contents/interview:guidelines-practice-cardio-renal-protection-patients-diabetes

Professor José Rodriguez Palomares co-chaired the guideline task force on 2024 ESC Guidelines for the Management of Peripheral Arterial and Aortic Diseases.

Video: https://medicaldigest.org/scientific-contents/interview:2024-esc-guidelines-management-peripheral-arterial-and-aortic-diseases

Professor Iris Grunwald shares her experience of personalised stroke management.

Video: https://medicaldigest.org/scientific-contents/interview:dundee-experience-really-personalised-acute-stroke-treatment

Professor Johanne Silvain presented results of the ABYSS trial in a Hot Line session at ESC Congress 2024. The cardiovascular safety of interrupting beta-blocker could not be shown in comparison to continuation in patients with a history of myocardial infarction and there was no benefit to the patients’ quality of life, according to late-breaking research presented.

Video: https://medicaldigest.org/scientific-contents/interview:beta-blocker-interruption-patients-prior-myocardial-infarction-results-abyss-trial-and-effect-blood-pressure-and-heart-rate-control